industry pr

Press release news from the public relations clients of Tiziani Whitmyre, Inc.

Posts Tagged ‘rainstorm microdroplet-based technology platform’


Wednesday, September 23rd, 2009

RainDance Expands Sequence Enrichment Solution Capabilities with 20,000 Amplicon Library and Whole Genome Amplification Protocol

rdt-702290 PROVIDENCE, RHODE ISLAND, U.S.A., September 23, 2009 RainDance Technologies, Inc., a leading provider of innovative microdroplet-based solutions for health and human disease research, announced today it has expanded the capabilities of its Sequence Enrichment Solution to enable the resequencing of up to 20,000 PCR targets. In addition, RainDance said it has become the first to support whole genome amplified samples for targeted resequencing.

In a presentation at Cambridge Healthtech Institute’s Exploring Next-Generation Sequencing conference, the company said these new enhancements represent a logical evolution of the RainDance technology platform and will add attractive benefits for the researcher investigating rare variants in large populations that cause cancer and other devastating diseases.

“With these expanded capabilities, we expect the market will accelerate its adoption of the RDT 1000, the centerpiece of our Sequence Enrichment Solution, for targeted resequencing studies across all genomic research sectors and in conjunction with all next-generation sequencing platforms,” said Christopher McNary, President and Chief Executive Officer, RainDance Technologies. “Our aggressive development program is rapidly creating new high-value protocols and applications, enabling RDT 1000 customers to increase the speed of their research into complex diseases,” said McNary.

Expanded Primer Library Enables Broader View of Human Genome

RainDance said it has expanded the content of its DNA primer library from 4,000 amplicons to 20,000 amplicons, while maintaining the precision provided by microdroplet-based PCR. This will allow researchers to incorporate a broader range of content for their large-scale targeted resequencing studies and to broaden their view of the human genome.

“Workflow and sample requirements will not change as the content is scaled up to 20,000 amplicons,” McNary said. “Our Sequence Enrichment Solution will maintain its performance and continue to provide the highest-quality data and sample uniformity.”

The company said the expanded DNA libraries will be available in the first quarter of 2010 and can be ordered through RainDance sales channels and service providers.

Whole Genome Amplification Protocol Supports Small Sample Sequencing

RainDance also announced it is the first company to support the use of whole genome amplified DNA samples for sequence enrichment. This capability will enable researchers to conduct studies with sample quantities that were previously too small for targeted resequencing. Now scientists can perform whole genomic amplification (WGA) on rare or small samples that have very low amounts of DNA, such as those found in tumor biopsies.

“The results of our studies demonstrate that RainDance’s Sequence Enrichment Solution is fully compatible with WGA samples and delivers the same high-quality results as assays performed with unamplified data,” said McNary.

The company said its WGA protocol is available now and has been validated using kits from Qiagen, GE Healthcare, and BioHelix Corporation. The kits can be ordered from their respective manufacturers.

“Both our expanded content library and WGA protocol are exceptionally easy to use and work seamlessly with our Sequence Enrichment Solution and RDT 1000 system,” McNary said. “These new capabilities are the first of many exciting applications for microdroplet-based PCR that RainDance will introduce in the coming weeks. These enhancements will help researchers rethink the way they design resequencing studies and will encourage new approaches to discovery. They will use the same proven hardware, consumables, and reagents presently available for our commercial solution,” he said.

About RainDance Technologies, Inc.

RainDance Technologies, Inc., is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s RainStorm™ technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted sequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

For more information, please visit www.raindancetech.com.

RainStorm is a trademark of RainDance Technologies, Inc.

# # #

Public Relations contact, Boston: Tiziani Whitmyre Inc., http://www.tizinc.com/public-relations

Bookmark and Share

Tuesday, September 22nd, 2009

RainDance Technologies and CLC bio Collaborate to Develop Specialized Software Solutions for Targeted Resequencing

rdt-702290Lexington, Massachusetts, U.S.A., and Aarhus, Denmark – September 17, 2009 – RainDance Technologies and CLC bio today announced a partnership to develop specialized software for the analysis of targeted resequencing data generated by workflows incorporating RainDance’s Sequence Enrichment Solution and next-generation DNA sequencing platforms.

“The rapid and efficient analysis of genomic data plays an important role in searching for the variants in large populations that cause cancer and other devastating diseases,” said Christopher McNary, President and Chief Executive Officer, RainDance Technologies. “By partnering with CLC bio, we can supply researchers with a solution that leverages the power of our innovative microdroplet-based technology to provide the highest-quality results in a simple yet powerful workflow. This capability will help accelerate the advent of personalized medicine and make profound contributions to health and human disease research,” he said.

CLC bio’s Chief Executive Officer, Thomas Knudsen, continues, Having decided to focus on high-throughput sequencing technologies several years ago, we’re constantly monitoring the market to identify new and complementary technologies being developed. The sequence enrichment platform from RainDance Technologies is truly innovative, and we are very much looking forward to making it even more valuable in supporting the full scientific workflow of their customers. We are proud to partner with RainDance on helping global science gain new ground.”

As a first step, CLC bio will release an expansion of its CLC Genomics Workbench, enabling scientists to analyze data faster and more effectively when using the RainDance solution for large-scale targeted resequencing studies. The software is already in use by RainDance scientists and will be released for commercial sale later this month.

The CLC bio/RainDance solution can be used with any next-generation sequencing workflow, giving customers the freedom to choose between the Illumina Genome Analyzer, Roche 454, or ABI SOLiD systems.

In the future, the partnership will continue to release specialized reports, data analyses, and workflow support for platform-independent targeted resequencing research that will provide additional value to RainDance customers.

To read more about CLC bio’s customized solutions, go to:

http://www.clcbio.com/index.php?id=485

About RainDance Technologies, Inc.

RainDance Technologies, Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s RainStorm™ technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted sequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

For more information, please visit www.raindancetech.com.

RainStorm™ is a trademark of RainDance Technologies, Inc.

About CLC bio

http://www.clcbio.com/about

# # #

Public Relations contact, Boston: Tiziani Whitmyre Inc., http://www.tizinc.com/public-relations

Bookmark and Share

Wednesday, June 10th, 2009

RainDance Technologies Announces Shipment of RDT 1000, Sequence Enrichment Solution to TGen Researchers

rdt-702290LEXINGTON, MASSACHUSETTS, U.S.A, June 10, 2009RainDance Technologies, Inc., today announced the shipment of an RDT 1000 and Sequence Enrichment Solution to the Translational Genomics Research Institute (TGen).

RainDance is a provider of innovative microdroplet-based solutions for human health and disease research.

TGen, a nonprofit biomedical research institute based in Phoenix, Arizona, focuses on the translation of laboratory discoveries into personalized medicine, developing earlier diagnostics and better treatments for patients with many forms of cancer, neurological and cardiovascular diseases, and infectious diseases.

Dr. David Duggan, an Investigator in TGen’s Genetic Basis of Human Disease Division, said one of the initial applications of the RainDance solution would focus on resequencing regions of the human genome identified as part of genome-wide association studies.

“The RainDance technology has tremendous breadth. We are also discussing its use in candidate gene and pathways studies, as well as targeting known disease-causing genes,” Dr. Duggan said.

Dr. Jeffrey Trent, TGen’s President and Research Director, said the use of RainDance products should further improve the speed and quality of TGen’s cutting-edge scientific investigations.

“TGen should significantly reduce the time required to conduct experiments by exponentially accelerating multiple applications for genome-level partitioning, including the generation of large amounts of targeted resequencing data,’’ Dr. Trent said.

“TGen is a recognized leader in the application of next-generation sequencing technologies to translational medicine research,” said Christopher McNary, President and Chief Executive Officer of RainDance Technologies. “Our Sequence Enrichment Solution and RDT 1000 system will accelerate their ability to perform large-scale targeted resequencing studies that will help realize the exciting benefits of personalized medicine.”

The RainDance solution consists of the RDT 1000 instrument, consumables kits, and custom PCR primer libraries. The solution uses RainDance’s breakthrough RainStormmicrodroplet-based technology platform.

The simplicity and speed of the technology are designed to maximize the efficiency of next-generation DNA sequencing workflows. The RDT 1000 generates picoliter-volume PCR reactions at the rate of 10 million discrete reactions per hour. High-speed sample processing is further enhanced by the fact that the Sequence Enrichment Solution uses a library of PCR primers in droplets enabling the amplification of hundreds to thousands of genomic loci in a single tube. The technology leverages the specificity of PCR to provide high breadth of coverage for the regions of interest.

The RainStorm format avoids the limitations of traditional multiplex hybridization and amplification technologies. RainDance’s solution minimizes process-induced bias or error and requires only a few micrograms of genomic DNA.

The commercial version of the Sequence Enrichment Solution is now being shipped in North America and will soon be delivered to the company’s first customer in Europe. For more information, contact info@raindancetech.com, call 781-861-6300, or visit the company’s Website at www.raindancetech.com.

About RainDance Technologies, Inc.

RainDance Technologies, Inc., is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s RainStorm™ technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted sequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

For more information, please visit www.raindancetech.com.

RainStorm™ is a trademark of RainDance Technologies, Inc.

About TGen

The Translational Genomics Research Institute (TGen) is a nonprofit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit www.tgen.org.

# # #

Notes to Editors:

Bookmark and Share

Industry PR is proudly powered by WordPress.
WordPress